These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

718 related items for PubMed ID: 26559529

  • 1. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD, Lacy BE, Rao T, Earnest DL.
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [Abstract] [Full Text] [Related]

  • 2. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A, Rybalov S.
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [Abstract] [Full Text] [Related]

  • 3. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J, Zakari M, Lembo AJ.
    Expert Opin Pharmacother; 2015 Mar; 16(18):2781-92. PubMed ID: 26558923
    [Abstract] [Full Text] [Related]

  • 4. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
    Brenner DM, Sayuk GS.
    Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
    [Abstract] [Full Text] [Related]

  • 5. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
    Lacy BE.
    Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
    [Abstract] [Full Text] [Related]

  • 6. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS.
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [Abstract] [Full Text] [Related]

  • 7. New treatment options for irritable bowel syndrome with predominant diarrhea.
    Weber HC.
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
    [Abstract] [Full Text] [Related]

  • 8. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
    Liu R, Staller K.
    Drug Des Devel Ther; 2020 Feb; 14():1391-1400. PubMed ID: 32308371
    [Abstract] [Full Text] [Related]

  • 9. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.
    Scarpellini E, Laterza L, Ianiro G, Tack J, Abenavoli L, Gasbarrini A.
    Expert Opin Pharmacother; 2016 Jul; 17(10):1395-402. PubMed ID: 27267380
    [Abstract] [Full Text] [Related]

  • 10. Modern Management of Irritable Bowel Syndrome: More Than Motility.
    Tack J, Vanuytsel T, Corsetti M.
    Dig Dis; 2016 Jul; 34(5):566-73. PubMed ID: 27331917
    [Abstract] [Full Text] [Related]

  • 11. Dietary and pharmacological treatment of abdominal pain in IBS.
    Camilleri M, Boeckxstaens G.
    Gut; 2017 May; 66(5):966-974. PubMed ID: 28232472
    [Abstract] [Full Text] [Related]

  • 12. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
    Keating GM.
    Drugs; 2017 Jun; 77(9):1009-1016. PubMed ID: 28493170
    [Abstract] [Full Text] [Related]

  • 13. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
    Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, Covington PS.
    N Engl J Med; 2016 Jan 21; 374(3):242-53. PubMed ID: 26789872
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.
    Brenner DM, Sayuk GS, Gutman CR, Jo E, Elmes SJR, Liu LWC, Cash BD.
    Am J Gastroenterol; 2019 Sep 21; 114(9):1502-1511. PubMed ID: 31356229
    [Abstract] [Full Text] [Related]

  • 15. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
    Fant RV, Henningfield JE, Cash BD, Dove LS, Covington PS.
    Clin Gastroenterol Hepatol; 2017 Jul 21; 15(7):1021-1029.e6. PubMed ID: 28167156
    [Abstract] [Full Text] [Related]

  • 16. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
    Corsetti M, Whorwell P.
    Expert Rev Gastroenterol Hepatol; 2017 Apr 21; 11(4):285-292. PubMed ID: 28276811
    [Abstract] [Full Text] [Related]

  • 17. Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.
    Brenner DM, Sayuk GS, Abel JL, Burslem K.
    J Manag Care Spec Pharm; 2021 Apr 21; 27(4):469-477. PubMed ID: 33769858
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.
    Am J Gastroenterol; 2004 Nov 21; 99(11):2195-203. PubMed ID: 15555002
    [Abstract] [Full Text] [Related]

  • 19. Eluxadoline: First Global Approval.
    Garnock-Jones KP.
    Drugs; 2015 Jul 21; 75(11):1305-10. PubMed ID: 26149369
    [Abstract] [Full Text] [Related]

  • 20. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
    Jones J, Lembo A, Heidelbaugh J, Kuritzky L, Lacy B.
    Curr Med Res Opin; 2021 Apr 21; 37(4):567-578. PubMed ID: 33566707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.